CIK 0001907108 · <br>Emerging growth company
Lexeo Therapeutics, Inc.
Sign in to watch- Ticker
- LXEO
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 854012572
- Phone
- (212) 547-9879
- Business address
- 345 PARK AVENUE SOUTH, FLOOR 6, NEW YORK, NY, 10010
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $43,228
- in 3 filings
Net −$43,228. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-01-07 | Adler Eric Chief Medical Officer | Grant or award | +43,750 | 70,625 | ||
| 2025-01-07 | Adler Eric Chief Medical Officer | Grant or award · Stock Option (right to buy) | +87,500 | 87,500 | ||
| 2024-12-10 | Townsend Richard Nolan Chief Executive Officer | Option exercise 10b5-1 | +2,500 | $2.33 | $6K | 123,195 |
| 2024-12-10 | Townsend Richard Nolan Chief Executive Officer | Sale 10b5-1 | −2,500 | $8.20 | $20K | 120,695 |
| 2024-12-10 | Townsend Richard Nolan Chief Executive Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −2,500 | 118,655 | ||
| 2024-11-25 | CHOLMONDELEY PAULA H Director | Purchase | +15,000 | $6.99 | $105K | 30,627 |
| 2024-11-11 | Tanguler Tolga Director | Grant or award · Stock Option (right to buy) | +36,000 | 36,000 | ||
| 2024-11-11 | Townsend Richard Nolan Chief Executive Officer | Option exercise 10b5-1 | +2,500 | $2.33 | $6K | 123,195 |
| 2024-11-11 | Townsend Richard Nolan Chief Executive Officer | Sale 10b5-1 | −2,500 | $7.82 | $20K | 120,695 |
| 2024-11-11 | Townsend Richard Nolan Chief Executive Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −2,500 | 121,155 | ||
| 2024-10-10 | Townsend Richard Nolan Chief Executive Officer | Option exercise 10b5-1 | +5,000 | $2.33 | $12K | 125,695 |
| 2024-10-10 | Townsend Richard Nolan Chief Executive Officer | Sale 10b5-1 | −5,000 | $8.10 | $40K | 120,695 |
| 2024-10-10 | Townsend Richard Nolan Chief Executive Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −5,000 | 123,655 | ||
| 2024-09-10 | Townsend Richard Nolan Chief Executive Officer | Option exercise 10b5-1 | +5,000 | $2.33 | $12K | 125,695 |
| 2024-09-10 | Townsend Richard Nolan Chief Executive Officer | Sale 10b5-1 | −5,000 | $10.65 | $53K | 120,695 |
| 2024-09-10 | Townsend Richard Nolan Chief Executive Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −5,000 | 128,655 | ||
| 2024-08-12 | Townsend Richard Nolan Chief Executive Officer | Option exercise 10b5-1 | +5,000 | $2.33 | $12K | 125,695 |
| 2024-08-12 | Townsend Richard Nolan Chief Executive Officer | Sale 10b5-1 | −5,000 | $11.53 | $58K | 120,695 |
| 2024-08-12 | Townsend Richard Nolan Chief Executive Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −5,000 | 133,655 | ||
| 2024-07-11 | Townsend Richard Nolan Chief Executive Officer | Sale 10b5-1 | −27,931 | $17.06 | $477K | 120,795 |
Page 6 of 9 · 165 trades